In a recent move that caught the attention of investors, Laura E. Niklason, the President, CEO, and Director of Humacyte, Inc. (NASDAQ:HUMA), has sold a significant portion of her holdings in the company. The transactions, which occurred on September 9 and 10, 2024, involved the sale of 157,704 shares at an average price of $5.42 on the first day, and 288,674 shares at an average price of $5.23 on the following day. The sales were reportedly made to pay down leverage and to provide a mechanism for investors to acquire shares at a time when Humacyte was not conducting a financing transaction and was not making any additional shares available for purchase.
Author: Investing.com
Published at: 2024-09-11 21:53:45
Still want to read the full version? Full article
